Core Insights - Polyrizon Ltd. announced promising preclinical results for its PL-14 Allergy Blocker, indicating its potential as a barrier-forming treatment for allergic rhinitis [1][3] - The study, conducted with the University of Parma, showed over 60% deposition of PL-14 in the nasal vestibule, crucial for blocking allergen contact [2][3] - The global allergen blocker market is projected to grow from USD 0.14 billion in 2024 to USD 0.21 billion by 2033, with a CAGR of 4.4% [4] Company Overview - Polyrizon specializes in developing intranasal products, particularly hydrogel-based nasal sprays that create a barrier against allergens and viruses [6] - The company's proprietary Capture & Contain (C&C) platform aims to deliver a high concentration of hydrogel to the nasal vestibule, enhancing its effectiveness [4][5] - Polyrizon is advancing its C&C platform towards clinical trials following successful preclinical validation [5]
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study